Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy

William McCoull, Scott Boyd, Martin R. Brown, Muireann Coen, Olga Collingwood, Nichola L. Davies, Ann Doherty, Gary Fairley, Kristin Goldberg, Elizabeth Hardaker, Guang He, Edward J. Hennessy, Philip Hopcroft, George Hodgson, Anne Jackson, Xiefeng Jiang, Ankur Karmokar, Anne-Laure Lainé, Nicola Lindsay, Yumeng Mao, Roshini Markandu, Lindsay McMurray, Neville McLean, Lorraine Mooney, Helen Musgrove, J. Willem M. Nissink, Alexander Pflug, Venkatesh Pilla Reddy, Philip B. Rawlins, Emma Rivers, Marianne Schimpl, Graham F. Smith, Sharon Tentarelli, Jon Travers, Robert I. Troup, Josephine Walton, Cheng Wang, Stephen Wilkinson, Beth Williamson, Jon Winter-Holt, Dejian Yang, Yuting Zheng, Qianxiu Zhu, and Paul D. Smith.  Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy.  Journal Of Medicinal Chemistry. 2021; Article ASAP.  doi: 10.1021/acs.jmedch